Results 11 to 20 of about 557 (132)

Efficacy of CagriSema for Reaching Anthropometric Treatment Targets and Cardiometabolic Outcomes: A Secondary, Post hoc Analysis of REDEFINE 1 [PDF]

Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 9317-9325, October 2026.
ABSTRACT Aims To assess the added value of absolute anthropometric targets alongside percentage weight loss in the clinical management of obesity. Materials and Methods The phase 3a, 68‐week REDEFINE 1 trial randomised adults without diabetes with BMI ≥ 30 kg/m2, or ≥ 27 kg/m2 with ≥ 1 obesity‐related complication, to once‐weekly CagriSema 2.4 mg/2.4 ...
Luca Busetto, Cynthia Osorto Contreras, Mikkel Hovden Christensen, Timothy W. Garvey, Deborah B. Horn, Barbara McGowan, Claire Prener Miller, Volker Schnecke, Carel W. le Roux   +8 more
wiley   +3 more sources

Current and Emerging Parenteral and Peroral Medications for Weight Loss: A Narrative Review [PDF]

Diseases
Obesity is a growing global health challenge, necessitating effective treatment options beyond lifestyle interventions. This narrative review explores established and emerging pharmacotherapies for weight management, including parenteral agents like ...
Abdullah Al Lawati, Ayman Alhabsi, Rhieya Rahul, Maria-Luisa Savino, Hamed Alwahaibi, Srijit Das, Hanan Al Lawati   +6 more
doaj   +6 more sources

Comparative Effectiveness of CagriSegma, Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta‐Analysis of Randomized Clinical Trials [PDF]

Endocrinology, Diabetes & Metabolism
Background Obesity is a chronic, progressive disease affecting over 1 billion adults worldwide, linked to serious comorbidities, including diabetes, hypertension, and cardiovascular disease and associated with increased mortality.
Sultan Hamarsheh, Abdel Rahman Jaber, Omar Abu‐Khazneh, Celina R. Andonie, Saleem Majadleh, Anwar Zahran, Hazem Ayesh   +6 more
doaj   +3 more sources

Comparative efficacy and safety of glucagon-like peptide 1 based drugs for weight loss in adults with overweight or obesity without diabetes: network meta-analysis of randomised controlled trials [PDF]

BMJ Medicine
Objective To compare the efficacy and safety of glucagon-like peptide 1 (GLP-1) based drug treatments for weight loss in adults with overweight or obesity without diabetes.Design Network meta-analysis of randomised controlled trials.Data sources Embase ...
Jing Zhang, Min Chen, Hao Sun, Yongze Li, Bing Ma, Weiwei Wang, Yanli Cao, Deshi Chen, Linlin Gong, Zihan Liu, Hongying Zha, Shuaibo Du, Wenxin Sun, Qiqiang Guo   +13 more
doaj   +3 more sources

Cardiovascular effects of incretin-based drugs in patients with and without a history of heart failure: a protocol for a systematic review, meta-analysis and trial sequential analysis of randomised controlled trials [PDF]

BMJ Open
Background Incretin-based drugs, including glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) and dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 RAs, are increasingly used in the management of type 2 diabetes mellitus and obesity ...
Matthew Meng Yang Lee, Janus C Jakobsen, Jens Dahlgaard Hove, Mohammed El-Sheikh, Johannes Grand, Christina Dam Bjerregaard Sillassen, Frederik Dencker Wisborg, Carsten Dirksen   +7 more
doaj   +4 more sources

Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity

Cardiology in Review, 2023
Despite the worldwide epidemic of obesity, there remain few approved pharmacological treatment options to bridge the gap between lifestyle therapy and bariatric surgery. Cagrilintide is an amylin-analog, now being developed in combination with the GLP-1 agonist semaglutide to achieve sustained weight loss in persons with overweight and obesity. Amylin,
Antonella M, D'Ascanio, Jamie A, Mullally, William H, Frishman   +2 more
openaire   +3 more sources

Amylin-based obesity therapy: a meta-analysis of Cagrilintide and CagriSema versus placebo. [PDF]

Ann Med Surg (Lond)
Background: Obesity remains a major global health challenge, driving demand for effective pharmacotherapies. Cagrilintide, a once-weekly amylin receptor agonist, and its fixed-dose combination with semaglutide ...
Yaseen M, Ameer A, Ali Z, Jamali JA, Kumar A, Basit Ali Siddiqui M, Kumari P, Hassaan M, Nanwani P, Abdul Basit M, Lohana N, Qureshi R, Tesfaye M.   +12 more
europepmc   +2 more sources

Amylin Analogs: The Next Major Class of Weight Loss Therapy: A Review of Experimental Data and Early-Phase Clinical Trials. [PDF]

Diabetes Obes Metab
Aims The management of the disease of obesity has been transformed by incretin‐based therapies; however, additional and alternative therapeutic strategies are needed to address its biological complexity. This narrative review examines
Alhazmi A, le Roux CW.
europepmc   +2 more sources

Novel Amylin‐Based Therapies for Weight Management in Adults With Overweight or Obesity Without Diabetes: A Network Meta‐Analysis [PDF]

Endocrinology, Diabetes & Metabolism
Background Long‐acting amylin‐based therapies (ABTs) are emerging anti‐obesity agents; we sought to compare their effects on weight and anthropometric outcomes in adults with overweight/obesity without diabetes, evaluate gastrointestinal (GI) safety, and
A. B. M. Kamrul‐Hasan, Ibrahim Khalil, Kunal Mahajan, Deep Dutta, Mainak Banerjee, Joseph M. Pappachan   +5 more
doaj   +2 more sources

Mitochondrial Adaptations in Skeletal Muscle Following Incretin‐Based Therapies: In Vitro [PDF]

Journal of Cachexia, Sarcopenia and Muscle
Background Incretin‐based therapies such as glucagon‐like peptide‐1 receptor agonists (GLP‐1Ras), dual GLP‐1/GIP agonists and amylin analogues have demonstrated significant weight loss benefits.
Victoria Old, Melanie Davies, Matthew Denniff, Pratik Choudhary, Nicholas Eastley, Robert U. Ashford, Emma Watson   +6 more
doaj   +2 more sources